News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Avastin Misses Endpoint in Pancreatic Cancer Study
November 13, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Nov 13 (Reuters) - Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Roche
MORE ON THIS TOPIC
Series A
New biotech cAMPfield emerges with $180M to reshape IBD treatment
June 18, 2026
·
2 min read
·
Gabrielle Masson
Insights
From fragile skin to living medicine: Lessons from RDEB
June 18, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Pancreatic cancer
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution
June 18, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Biogen makes up to $1B immuno play with RayThera takeover
June 18, 2026
·
2 min read
·
Tristan Manalac
